Next Article in Journal
Noncoding Subgenomic Flavivirus RNA: Multiple Functions in West Nile Virus Pathogenesis and Modulation of Host Responses
Next Article in Special Issue
Challenges in Mucosal HIV Vaccine Development: Lessons from Non-Human Primate Models
Previous Article in Journal
HSV-2 Vaccine: Current Status and Insight into Factors for Developing an Efficient Vaccine
Previous Article in Special Issue
Recombinant Salmonella enterica Serovar Typhimurium as a Vaccine Vector for HIV-1 Gag
Article Menu

Export Article

Open AccessCommunication
Viruses 2014, 6(2), 391-403; https://doi.org/10.3390/v6020391

Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines

1
Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Via GB. Grassi 74, 20157 Milan, Italy
2
Department of Chemistry, University of Milan, Via C.Golgi 19, 20133 Milan, Italy
3
Unit of Obstetrics and Gynecology, Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Via GB. Grassi 74, 20157 Milan, Italy
4
Department of Pathophysiology and Transplantation, University of Milan, Via F.lli VCervi 93, 20090 Milan, Italy
5
Don C. Gnocchi Foundation, IRCCS, Via Capecelatro 66, 20148 Milan, Italy
*
Author to whom correspondence should be addressed.
Received: 22 November 2013 / Revised: 7 January 2014 / Accepted: 20 January 2014 / Published: 27 January 2014
(This article belongs to the Special Issue AIDS Vaccine 2014)
View Full-Text   |   Download PDF [1030 KB, uploaded 12 May 2015]   |  

Abstract

The development of new and effective adjuvants may play a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably toll like receptors (TLRs). Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand Polyman 19 (PM 19) to modulate innate immune responses. Results showed that PM 19 alone, or in combination with TLR agonists, induces the expression of cytokines, β chemokines and co-stimulatory molecules that may, in turn, modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated. View Full-Text
Keywords: vaccine; HIV-1; adjuvant; DC-SIGN; innate immunity; glycomimetic compounds vaccine; HIV-1; adjuvant; DC-SIGN; innate immunity; glycomimetic compounds
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Berzi, A.; Varga, N.; Sattin, S.; Antonazzo, P.; Biasin, M.; Cetin, I.; Trabattoni, D.; Bernardi, A.; Clerici, M. Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines. Viruses 2014, 6, 391-403.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top